How much does MOUNJARO (Tirzepatide Injection) Cost& price without insurance in China?
MOUNJARO® is the commercial brand name of Tirzepatide Injection, developed by Eli Lilly and Company. It is a once-weekly dual GLP‑1 and GIP receptor agonist for subcutaneous injection. It activates two intestinal hormone receptors simultaneously to suppress glucagon release, slow gastric emptying and reduce appetite, achieving glucose-dependent hypoglycemic effects while bringing prominent benefits in weight management and cardiovascular protection.
Main Indications
Improvement of glycemic control in adult patients with type 2 diabetes mellitus, usable as monotherapy or combined with other hypoglycemic agents;
Chronic weight management for overweight or obese adults with weight-related comorbidities.
Clinical Research
Global multicenter clinical programs fully verified its comprehensive therapeutic advantages. Glycemic control trials confirmed steady and prominent reduction of glycosylated hemoglobin with weekly single injection dosing. Weight management trials delivered superior body weight lowering effects compared with single-target GLP‑1 agonists. Cardiovascular outcome trials demonstrated obvious cardiovascular protective effects for diabetic patients with high vascular risk. Tolerability observation showed mild gastrointestinal discomfort mainly occurring during dose titration phases and gradually alleviating with prolonged administration, with low hypoglycemia risk under monotherapy. Long-term follow-up studies proved sustained stable efficacy and controllable overall safety spectrum.
Common Side Effects
Common mild adverse reactions: Nausea, vomiting, diarrhea, decreased appetite and mild injection site redness;
Laboratory abnormalities: Rare transient slight elevation of pancreatic enzymes;
Severe but uncommon risks: Severe hypoglycemia (mainly when combined with insulin or sulfonylureas), acute pancreatitis, thyroid C-cell tumor risk and systemic hypersensitivity responses.
Approval Status in China
MOUNJARO® (specification 0.5ml:10mg pre-filled pen, 4 pens per box) obtained marketing approval in China in 2025. It is a subcutaneous injectable prescription drug for diabetes and weight management.
Buy MOUNJARO (Tirzepatide Injection) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
